Curebase Appoints Two Clinical Trial Veterans to New Advisory Board

Curebase's mission is to accelerate the delivery of high-quality medical innovations to patients while also improving human well-being through more efficient clinical trials.

Fremont, CA: Curebase, a company dedicated to democratizing clinical study access, has appointed Dr. Aaron Kamauu and Dr. Amir Lahav to its Advisory Board. The new board members will assist the company in developing technology, data, partnership, and growth strategies to increase its market share in the global decentralized clinical trial (DCT) market.

Curebase's diversified model allows for the inclusion of underrepresented patient populations that would otherwise be excluded from clinical trials. In addition, patients can participate in clinical studies regardless of their location, thanks to its virtual research sites. The Cubase platform enables sponsors, CROs, and physicians from all sizes of practices, including private practices, independent clinics, and extensive academic research sites, to conduct clinical research more efficiently.

Dr. Kamauu is the managing director of Ikaika Health. This consulting firm focuses on leveraging Real-World Data (RWD) to support a variety of clinical research, informatics, clinical trials, and drug development activities. Before joining Ikaika, he worked for Parexel as vice president of real-world data services and as the founder and CEO of Anolinx, a healthcare data, and biomedical informatics startup.

Dr. Kamauu graduated from the University of Utah School of Medicine with a medical degree and master's degree in public health and biomedical informatics. Dr. Kamauu is a member of several prestigious medical societies, where he has presented cutting-edge research in clinical research informatics, public health informatics, and radiology/imaging informatics.

"We've reached a point of acceptance with decentralised clinical trials, and now we're at the point of iteration and evolution," Dr. Kamauu said. "Curebase is doing an excellent job with this. The Curebase platform, in particular, is robust and flexible, avoiding becoming locked into a large infrastructure that may be robust but not very flexible. I'm excited to collaborate with Curebase on expanding how they leverage and generate RWD in support of clinical research."

Dr. Lahav is the head of strategic R&D for digital healthcare innovation at Mitsubishi Tanabe Pharma Holdings America and an industry leader in developing digital biomarkers for neurodegenerative diseases using artificial intelligence/machine learning. He is also Redenlab's chief of digital health and strategy. His previous positions included executive director and head of digital medicine at Karyopharm Therapeutics and digital health and clinical innovation lead for rare diseases at Pfizer.

"Dr. Lahav and Dr. Kamauu are two of the most innovative and forward-thinking physicians in the world," said Curebase CEO Tom Lemberg. "Their knowledge and experience will be invaluable in the further development of our platform and business strategy."